AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...
GlobalData on MSN8d
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacksAfter Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
Learn More » First, let's consider how Eli Lilly's newest products will affect its performance in the next half-decade. These new medicines include Alzheimer's disease treatment Kisunla ...
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback